Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
8.00
+1.99 (33.11%)
At close: Mar 9, 2026, 4:00 PM EDT
7.41
-0.59 (-7.37%)
After-hours: Mar 9, 2026, 5:37 PM EDT
Minerva Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
346.20M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 277.73M |
| Cellectis | 82.55M |
| Fennec Pharmaceuticals | 38.79M |
| OmniAb | 18.67M |
| Prelude Therapeutics | 10.50M |
| Ovid Therapeutics | 6.61M |
| Surrozen | 3.60M |
| Abeona Therapeutics | 400.00K |
NERV News
- 5 days ago - Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - GlobeNewsWire
- 6 weeks ago - Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 - GlobeNewsWire
- 3 months ago - Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors - GlobeNewsWire
- 4 months ago - Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 4 months ago - Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved - GlobeNewsWire
- 7 months ago - Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results - GlobeNewsWire
- 10 months ago - Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates - GlobeNewsWire